Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Key facts
- Where
- Shenyang, ChinaSee the site
Where in China
- Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)Shenyang, ChinaContact: Xingshun QiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- General Hospital of Shenyang Military Region
- Trial code
- NCT06483737
- Record updated
- 26 August 2025
- Original description
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.Read full original descriptionShow less
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.
Inclusion: A definite diagnosis of liver cirrhosis and overt HE; A serum albumin level of 23-30g/L; Age ≥18 years old; Sign the informed consent.
Exclusion: A history of transjugular intrahepatic portosystemic shunt; A diagnosis of acute liver failure; Severe heart and/or lung diseases; Psychiatric or nervous diseases; Contraindications to human albumin infusion; Pregnant or lactating.